1. Home
  2. BSL vs MDWD Comparison

BSL vs MDWD Comparison

Compare BSL & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BSL
  • MDWD
  • Stock Information
  • Founded
  • BSL 2010
  • MDWD 2000
  • Country
  • BSL United States
  • MDWD Israel
  • Employees
  • BSL N/A
  • MDWD N/A
  • Industry
  • BSL Trusts Except Educational Religious and Charitable
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • BSL Finance
  • MDWD Health Care
  • Exchange
  • BSL Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • BSL 186.5M
  • MDWD 184.8M
  • IPO Year
  • BSL N/A
  • MDWD 2014
  • Fundamental
  • Price
  • BSL $14.34
  • MDWD $19.83
  • Analyst Decision
  • BSL
  • MDWD Strong Buy
  • Analyst Count
  • BSL 0
  • MDWD 1
  • Target Price
  • BSL N/A
  • MDWD $25.00
  • AVG Volume (30 Days)
  • BSL 71.9K
  • MDWD 65.3K
  • Earning Date
  • BSL 01-01-0001
  • MDWD 03-20-2025
  • Dividend Yield
  • BSL 9.55%
  • MDWD N/A
  • EPS Growth
  • BSL N/A
  • MDWD N/A
  • EPS
  • BSL N/A
  • MDWD N/A
  • Revenue
  • BSL N/A
  • MDWD $19,720,000.00
  • Revenue This Year
  • BSL N/A
  • MDWD $10.15
  • Revenue Next Year
  • BSL N/A
  • MDWD $25.62
  • P/E Ratio
  • BSL N/A
  • MDWD N/A
  • Revenue Growth
  • BSL N/A
  • MDWD N/A
  • 52 Week Low
  • BSL $12.19
  • MDWD $11.04
  • 52 Week High
  • BSL $14.56
  • MDWD $24.00
  • Technical
  • Relative Strength Index (RSI)
  • BSL 47.62
  • MDWD 63.06
  • Support Level
  • BSL $14.23
  • MDWD $17.47
  • Resistance Level
  • BSL $14.55
  • MDWD $18.79
  • Average True Range (ATR)
  • BSL 0.13
  • MDWD 1.06
  • MACD
  • BSL 0.01
  • MDWD 0.14
  • Stochastic Oscillator
  • BSL 44.74
  • MDWD 96.41

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage, which may increase the risk to the Fund.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: